(Circulation. 2000;102:2385.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
Efficacy and Safety of Oral Dofetilide in Converting to and Maintaining Sinus Rhythm in Patients With Chronic Atrial Fibrillation or Atrial Flutter
The Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) Study
From Veterans Affairs Medical Center, Washington, DC (S.S.); James A. Haley Medical Center (R.G.Z.), Tampa, Fla; Cardiology Associates Medical Group of East San Diego, Inc (L.Y.), San Diego, Calif; the Division of Cardiology, University of California–Irvine Medical Center (M.A.B.); the Division of Cardiology, University of California–San Diego Medical Center (G.K.F.); the Division of Cardiology, Presbyterian Hospital of Dallas (M.B.), Dallas, Tex; and Pfizer Inc (C.B.B.), Groton, Conn.
Correspondence to Dr Steven Singh, Veterans Affairs Medical Center, 50 Irving St NW, Room 1E301, Washington, DC 20422. E-mail snsingh{at}erols.com
Background—This double-blind, multicenter, placebo-controlled study determined the efficacy and safety of dofetilide in converting atrial fibrillation (AF) or atrial flutter (AFl) to sinus rhythm (SR) and maintaining SR for 1 year.
Methods and Results—Patients with AF or AFl (n=325) were randomized to 125, 250, or 500 µg dofetilide or placebo twice daily. Dosages were adjusted for QTc response and, after 105 patients were enrolled, for calculated creatinine clearance (ClCr). Pharmacological cardioversion rates for 125, 250, and 500 µg dofetilide were 6.1%, 9.8%, and 29.9%, respectively, versus 1.2% for placebo (250 and 500 µg versus placebo; P=0.015 and P<0.001, respectively). Seventy percent of pharmacological cardioversions with dofetilide were achieved in 24 hours and 91% in 36 hours. For the 250 patients who successfully cardioverted pharmacologically or electrically, the probability of remaining in SR at 1 year was 0.40, 0.37, 0.58 for 125, 250, and 500 µg dofetilide, respectively, and 0.25 for placebo (500 µg versus placebo, P=0.001). Two cases of torsade de pointes occurred, 1 on day 2 and the other on day 3 (0.8% of all patients given active drug); 1 sudden cardiac death, classified as proarrhythmic, occurred on day 8 (0.4% of all patients given active drug).
Conclusions—Dofetilide, a new class III antiarrhythmic agent, is moderately effective in cardioverting AF or AFl to SR and significantly effective in maintaining SR for 1 year. In-hospital initiation and dosage adjustment based on QTc and ClCr are necessary to minimize a small but nonnegligible proarrhythmic risk.
Key Words: antiarrhythmia agents • arrhythmia • fibrillation • atrial flutter
This article has been cited by other articles:
 |
|
 |
|
  C. Blomstrom-Lundqvist Drug treatment of supraventricular tachycardia Heart, November 1, 2009; 95(21): 1803 - 1807. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Shamiss, Y. Khaykin, R. Oosthuizen, D. Tunney, B. Sarak, M. Beardsall, C. Seabrook, L. Frost, Z. Wulffhart, B. Tsang, et al. Dofetilide is safe and effective in preventing atrial fibrillation recurrences in patients accepted for catheter ablation Europace, November 1, 2009; 11(11): 1448 - 1455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Piccini, V. Hasselblad, E. D. Peterson, J. B. Washam, R. M. Califf, and D. F. Kong Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J. Am. Coll. Cardiol., September 15, 2009; 54(12): 1089 - 1095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Arya, J. Silberbauer, S. L. Teichman, P. Milner, N. Sulke, and A. J. Camm A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology Europace, April 1, 2009; 11(4): 458 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. W. Khoo and G. Y. H. Lip Acute Management of Atrial Fibrillation Chest, March 1, 2009; 135(3): 849 - 859. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Geller, K. Egstrup, P. Kulakowski, M. Rosenqvist, M. A. Jansson, A. Berggren, N. Edvardsson, P. Sager, and H. J. Crijns Rapid Conversion of Persistent Atrial Fibrillation to Sinus Rhythm by Intravenous AZD7009 J. Clin. Pharmacol., March 1, 2009; 49(3): 312 - 322. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.#x.;n. Farré, H. J.J. Wellens, J.#x. M. Rubio, and J. Benezet CHAPTER 28 Supraventricular Tachycardias ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Camm, P. Kirchhof, G. Y.H. Lip, I. Savelieva, and S. Ernst CHAPTER 29 Atrial Fibrillation ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mykytsey, J. L. Bauman, M. Razminia, T. Zheutlin, T. Wang, M. Saleem, S. Leal, and R. F. Kehoe Observations on the Safety and Effectiveness of Dofetilide in Patients With Paroxysmal Atrial Fibrillation and Normal Left Ventricular Function Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2007; 12(1): 36 - 43. [Abstract] [PDF]
|
|
|
|
 |
|
 F. Lombardi, M. Borggrefe, W. Ruzyllo, B. Luderitz, and for the A-COMET-II Investigators Azimilide vs. placebo and sotalol for persistent atrial fibrillation: the A-COMET-II (Azimilide-CardiOversion MaintEnance Trial-II) trial Eur. Heart J., September 2, 2006; 27(18): 2224 - 2231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Writing Committee Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Europace, September 1, 2006; 8(9): 651 - 745. [Full Text] [PDF]
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society J. Am. Coll. Cardiol., August 15, 2006; 48(4): 854 - 906. [Full Text] [PDF]
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society J. Am. Coll. Cardiol., August 15, 2006; 48(4): e149 - e246. [Full Text] [PDF]
|
|
|
|
 |
|
 V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society Circulation, August 15, 2006; 114(7): e257 - e354. [Full Text] [PDF]
|
|
|
|
|
|
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society Circulation, August 15, 2006; 114(7): 700 - 752. [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Eur. Heart J., August 2, 2006; 27(16): 1979 - 2030. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lafuente-Lafuente, S. Mouly, M. A. Longas-Tejero, I. Mahe, and J.-F. Bergmann Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med, April 10, 2006; 166(7): 719 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. S. Nagra, G. S. Ledley, and B. K. Kantharia Marked QT Prolongation and Torsades de Pointes Secondary to Acute Ischemia in an Elderly Man Taking Dofetilide for Atrial Fibrillation: A Cautionary Tale Journal of Cardiovascular Pharmacology and Therapeutics, July 1, 2005; 10(3): 191 - 195. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Duytschaever, Y. Blaauw, and M. Allessie Consequences of atrial electrical remodeling for the anti-arrhythmic action of class IC and class III drugs Cardiovasc Res, July 1, 2005; 67(1): 69 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Grom, T. S. Faber, M. Brunner, C. Bode, and M. Zehender Delayed adaptation of ventricular repolarization after sudden changes in heart rate due to conversion of atrial fibrillation. A potential risk factor for proarrhythmia? Europace, January 1, 2005; 7(2): 113 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Palin, R. Kailasam, and C. W. Hogue Jr Atrial Fibrillation After Cardiac Surgery: Pathophysiology and Treatment Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2004; 8(3): 175 - 183. [Abstract] [PDF]
|
|
|
|
 |
|
 A. V Guanzon and M. A Crouch Phase IV Trial Evaluating the Effectiveness and Safety of Dofetilide Ann. Pharmacother., July 1, 2004; 38(7): 1142 - 1147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Chandra, T. S. Rosen, Z.-H. Yeom, K. Lee, H.-Y. Kim, P. Danilo Jr, and M. R. Rosen Evaluation of KCB-328, a new IKr blocking antiarrhythmic agent in pacing induced canine atrial fibrillation Europace, January 1, 2004; 6(5): 384 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. McNamara, L. J. Tamariz, J. B. Segal, and E. B. Bass Management of Atrial Fibrillation: Review of the Evidence for the Role of Pharmacologic Therapy, Electrical Cardioversion, and Echocardiography Ann Intern Med, December 16, 2003; 139(12): 1018 - 1033. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.J. Boos, J. Carlsson, and R.S. More Rate or rhythm control in persistent atrial fibrillation? QJM, December 1, 2003; 96(12): 881 - 892. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Committee Members, C. Blomstrom-Lundqvist, M. M. Scheinman, E. M. Aliot, J. S. Alpert, H. Calkins, A. J. Camm, W. B. Campbell, D. E. Haines, K. H. Kuck, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias --executive summary: a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) Developed in Collaboration with NASPE-Heart Rhythm Society J. Am. Coll. Cardiol., October 15, 2003; 42(8): 1493 - 1531. [Full Text] [PDF]
|
|
|
|
|
|
C. Blomstrom-Lundqvist, M. M. Scheinman, E. M. Aliot, J. S. Alpert, H. Calkins, A. J. Camm, W. B. Campbell, D. E. Haines, K. H. Kuck, B. B. Lerman, et al. ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias*--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias) Circulation, October 14, 2003; 108(15): 1871 - 1909. [Full Text] [PDF]
|
|
|
|
|
|
Committee Members, C. Blomstrom-Lundqvist, M. M Scheinman, E. M Aliot, J. S Alpert, H. Calkins, A.J. Camm, W.B. Campbell, D. E Haines, K. H Kuck, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: A Report of the American College of Cardiology/American HeartAssociation Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines(Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias)Developed in collaboration with NASPE-Heart Rhythm Society Eur. Heart J., October 2, 2003; 24(20): 1857 - 1897. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Capucci and D. Aschieri Antiarrhythmic drug therapy: what is certain and what is to come Eur. Heart J. Suppl., September 1, 2003; 5(suppl_H): H8 - H18. [Abstract] [PDF]
|
|
|
|
|
|
P. Touboul, J. Brugada, A. Capucci, H. J.G.M. Crijns, N. Edvardsson, and S. H. Hohnloser Dronedarone for prevention of atrial fibrillation: A dose-ranging study Eur. Heart J., August 2, 2003; 24(16): 1481 - 1487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Page, T. W. Tilsch, S. J. Connolly, D. J. Schnell, S. R. Marcello, W. E. Wilkinson, E. L.C. Pritchett, and for the Azimilide Supraventricular Arrhythmia Prog Asymptomatic or "Silent" Atrial Fibrillation: Frequency in Untreated Patients and Patients Receiving Azimilide Circulation, March 4, 2003; 107(8): 1141 - 1145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Falk Management of Atrial Fibrillation -- Radical Reform or Modest Modification? N. Engl. J. Med., December 5, 2002; 347(23): 1883 - 1884. [Full Text] [PDF]
|
|
|
|
|
|
G Nichol, F McAlister, B Pham, A Laupacis, B Shea, M Green, A Tang, and G Wells Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation Heart, June 1, 2002; 87(6): 535 - 543. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. G. Cosio and E. Delpon New Antiarrhythmic Drugs for Atrial Flutter and Atrial Fibrillation: A Conceptual Breakthrough at Last? Circulation, January 22, 2002; 105(3): 276 - 278. [Full Text] [PDF]
|
|
|
|
|
|
J. A. Reiffel Is it Rational, Reasonable or Excessive, and Consistently Applied? One View of the Increasing FDA Emphasis on Safety First for the Release and Use of Antiarrhythmic Drugs for Supraventricular Arrhythmias Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2001; 6(4): 333 - 339. [PDF]
|
|
|
|
|
|
A. Palinkas, E. Antonielli, E. Picano, A. Pizzuti, A. Varga, B. Nyuzo, J.M. Alegret, A. Bonzano, M. Tanga, A. Coppolino, et al. Clinical value of left atrial appendage flow velocity for predicting of cardioversion success in patients with non-valvular atrial fibrillation Eur. Heart J., December 1, 2001; 22(23): 2201 - 2208. [Abstract] [PDF]
|
|
|
|
|
|
V. Fuster, L. E. Ryden, R. W. Asinger, D. S. Cannom, H. J. Crijns, R. L. Frye, J. L. Halperin, G. N. Kay, W. W. Klein, S. Levy, et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology Circulation, October 23, 2001; 104(17): 2118 - 2150. [Full Text] [PDF]
|
|
|
|
|
|
Guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology Eur. Heart J., October 2, 2001; 22(20): 1852 - 1923. [PDF]
|
|
|
|
|
|
V. Fuster, L. E. Ryden, R. W. Asinger, D. S. Cannom, H. J. Crijns, R. L. Frye, J. L. Halperin, G. N. Kay, W. W. Klein, S. Levy, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1231 - 1265. [Full Text] [PDF]
|
|
|
|
|
|
V. Fuster, L. E. Ryden, R. W. Asinger, D. S. Cannom, H. J. Crijns, R. L. Frye, J. L. Halperin, G. N. Kay, W. W. Klein, S. Levy, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1266 - 1266. [Full Text] [PDF]
|
|
|
|
|
|
T. Van Noord, I. C. Van Gelder, H. J.G.M. Crijns, S. Singh, R. G. Zoble, L. Yellen, M. A. Brodsky, G. K. Feld, M. Berk, and C. B. Billing Jr. Pericardioversion Dofetilide Does Not Suppress Immediate and Subacute Recurrences of Persistent Atrial Fibrillation Response Circulation, September 11, 2001; 104 (11): e57 - e57. [Full Text] [PDF]
|
|
|
|
|
|
O. D. Pedersen, H. Bagger, N. Keller, B. Marchant, L. Kober, and C. Torp-Pedersen Efficacy of Dofetilide in the Treatment of Atrial Fibrillation-Flutter in Patients With Reduced Left Ventricular Function: A Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) Substudy Circulation, July 17, 2001; 104(3): 292 - 296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. Falk Atrial Fibrillation N. Engl. J. Med., April 5, 2001; 344(14): 1067 - 1078. [Full Text] [PDF]
|
|
|
|
|
|
M. R. Lauer Dofetilide: is the treatment worse than the disease? J. Am. Coll. Cardiol., March 15, 2001; 37(4): 1106 - 1110. [Full Text] [PDF]
|
|
|
|
 |
|
 Dofetilide: A New Option for Patients with Atrial Fibrillation Journal Watch Cardiology, January 19, 2001; 2001(119): 1 - 1. [Full Text]
|
|